Last year, when noted researcher James Allison, PhD, won the Nobel Prize for Physiology or Medicine for his pioneering work that led to the development of groundbreaking oncology treatment, he took the occasion as an opportunity to decry what he said was a death of basic scientific research, as development for new pharmaceuticals is usually tied to closely guarded company data.
Last year, when noted researcher James Allison, PhD, won the Nobel Prize for Physiology or Medicine for his pioneering work that led to the development of groundbreaking oncology treatment, he took the occasion as an opportunity to decry what he said was a death of basic scientific research, as development for new pharmaceuticals is usually tied to closely guarded company data.
This week, The Washington Post reported that etanercept, sold as the blockbuster rheumatoid arthritis drug Enbrel by Amgen within the United States and by Pfizer in other territories, appeared to reduce the risk of Alzheimer disease by 64% when Pfizer researchers analyzed hundreds of thousands of insurance claims. The researchers urged the company to conduct a clinical trial to see if the effect was real, but after several years of discussion, Pfizer opted not to pursue that path, deeming that it held little chance of success.
Both Pfizer and Amgen denied that the decision was tied to commercial reasons; Enbrel has 2 biosimilar products approved (Eticovo and Erelzi), but neither is commercially available due to extensive patent litigation. Erelzi was approved in 2016, and within days after Eticovo’s April approval, Amgen, Hoffman-La Roche, and Immunex sued and alleged infringement of 5 patents.
Some outside scientists interviewed by the newspaper, which obtained confidential company papers detailing the findings and internal discussions, disagreed with the decision, noting that Alzheimer disease has no known treatment and has devastating consequences.
According to the Alzheimer’s Association, without any therapy advances, the disease is expected to cost the country as much as $1.1 trillion by 2050 and affect 15 million people. The bulk of care for this illness is currently borne by unpaid caregivers, currently valued at over $230 billion.
Similar to Allison when he discussed his prize-winning work last September, noting the long struggles he had with T-cell research that eventually led to checkpoint therapy (“You can understand something about a signal by knowing what didn’t happen,” he said), the researchers interviewed by the Post said that without publishing the data publicly or attempting a clinical trial, the scientific and Alzheimer community will not know if the drug truly has potential.
A trial would have cost at least $80 million, according to the report, and would have made little financial sense given the upcoming patent expirations on Enbrel and eventual biosimilar competition.
But researchers increasingly suspect that systemic inflammation holds clues to the inflammation that happens within the brain, and the Pfizer data isn’t the only set pointing to the anti-inflammatory potential of etanercept for Alzheimer. The newspaper noted that a similar study published in 2016 reached a similar conclusion. Exposure to anti—tumor necrosis factor agents like etanercept was associated with a lower risk of the brain disease.
In addition, the Pfizer researchers also found a similar effect when they looked at AbbVie’s innovator adalimumab product Humira, another anti-inflammatory drug enmeshed in patent thickets with approved but currently unmarketed biosimilar adalimumab options.
Enbrel and Humira are the 2 drugs that account for the largest share of drug spending in employer health plans.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).